125 related articles for article (PubMed ID: 24690180)
1. Interferon lambda 4 polymorphism affects on outcome of telaprevir, pegylated interferon and ribavirin combination therapy for chronic hepatitis C.
Nagaoki Y; Imamura M; Kawakami Y; Kan H; Fujino H; Fukuhara T; Kobayashi T; Ono A; Nakahara T; Naeshiro N; Urabe A; Yokoyama S; Miyaki D; Murakami E; Kawaoka T; Tsuge M; Hiramatsu A; Aikata H; Takahashi S; Hayes CN; Ochi H; Chayama K;
Hepatol Res; 2014 Dec; 44(14):E447-54. PubMed ID: 24690180
[TBL] [Abstract][Full Text] [Related]
2. Predictive value of the IFNL4 polymorphism on outcome of telaprevir, peginterferon, and ribavirin therapy for older patients with genotype 1b chronic hepatitis C.
Fujino H; Imamura M; Nagaoki Y; Kawakami Y; Abe H; Hayes CN; Kan H; Fukuhara T; Kobayashi T; Masaki K; Ono A; Nakahara T; Honda Y; Naeshiro N; Urabe A; Yokoyama S; Miyaki D; Murakami E; Kawaoka T; Hiraga N; Tsuge M; Hiramatsu A; Hyogo H; Aikata H; Takahashi S; Miki D; Ochi H; Ohishi W; Chayama K;
J Gastroenterol; 2014 Dec; 49(12):1548-56. PubMed ID: 24362944
[TBL] [Abstract][Full Text] [Related]
3. IFNL4 polymorphism effects on outcome of simeprevir, peginterferon, and ribavirin therapy for older patients with genotype 1 chronic hepatitis C.
Mori N; Imamura M; Kawakami Y; Nagaoki Y; Kawaoka T; Tsuge M; Hiramatsu A; Hayes CN; Aikata H; Miki D; Ochi H; Honda Y; Takaki S; Tsuji K; Chayama K;
Hepatol Res; 2017 Mar; 47(3):E5-E13. PubMed ID: 27027531
[TBL] [Abstract][Full Text] [Related]
4. Performance and Value of IFN-Lambda3 and IFN-Lambda4 Genotyping in Patients with Chronic Hepatitis C (CHC) Genotype 2/3 in a Real World Setting.
Wiegand SB; Heidrich B; Susser S; Rogalska-Taranta M; Petersen J; Böker KH; Grigorian N; Link R; Naumann U; John C; Lueth S; Malfertheiner P; Manns MP; Wedemeyer H; Sarrazin C; Cornberg M
PLoS One; 2015; 10(12):e0145622. PubMed ID: 26699619
[TBL] [Abstract][Full Text] [Related]
5. Polymorphisms of interferon-λ4 and IL28B - effects on treatment response to interferon/ribavirin in patients with chronic hepatitis C.
Stättermayer AF; Strassl R; Maieron A; Rutter K; Stauber R; Strasser M; Beinhardt S; Datz C; Scherzer TM; Steindl-Munda P; Gschwantler M; Trauner M; Hofer H; Ferenci P
Aliment Pharmacol Ther; 2014 Jan; 39(1):104-11. PubMed ID: 24205831
[TBL] [Abstract][Full Text] [Related]
6. KIR3DL1-HLA-Bw4 combination and IL28B polymorphism predict response to Peg-IFN and ribavirin with and without telaprevir in chronic hepatitis C.
Umemura T; Ota M; Katsuyama Y; Wada S; Mori H; Maruyama A; Shibata S; Nozawa Y; Kimura T; Morita S; Joshita S; Komatsu M; Matsumoto A; Kamijo A; Kobayashi M; Takamatsu M; Yoshizawa K; Kiyosawa K; Tanaka E
Hum Immunol; 2014 Aug; 75(8):822-6. PubMed ID: 24929144
[TBL] [Abstract][Full Text] [Related]
7. Interferon-lambda4 genetic polymorphism is associated with the therapy response for hepatitis C virus recurrence after a living donor liver transplant.
Konishi H; Motomura T; Matsumoto Y; Harimoto N; Ikegami T; Yoshizumi T; Soejima Y; Shirabe K; Fukuhara T; Maehara Y
J Viral Hepat; 2014 Jun; 21(6):397-404. PubMed ID: 24750545
[TBL] [Abstract][Full Text] [Related]
8. Interferon-λ3 polymorphisms in pegylated-interferon-α plus ribavirin therapy for genotype-2 chronic hepatitis C.
Ishiguro H; Abe H; Seki N; Sugita T; Aida Y; Itagaki M; Sutoh S; Shimada N; Furihata T; Tsubota A; Aizawa Y
World J Gastroenterol; 2015 Apr; 21(13):3904-11. PubMed ID: 25852275
[TBL] [Abstract][Full Text] [Related]
9. Predictive value of interferon-lambda gene polymorphisms for treatment response in chronic hepatitis C.
Susser S; Herrmann E; Lange C; Hamdi N; Müller T; Berg T; Perner D; Zeuzem S; Sarrazin C
PLoS One; 2014; 9(11):e112592. PubMed ID: 25393304
[TBL] [Abstract][Full Text] [Related]
10. Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C.
Furusyo N; Ogawa E; Nakamuta M; Kajiwara E; Nomura H; Dohmen K; Takahashi K; Satoh T; Azuma K; Kawano A; Tanabe Y; Kotoh K; Shimoda S; Hayashi J;
J Hepatol; 2013 Aug; 59(2):205-12. PubMed ID: 23542346
[TBL] [Abstract][Full Text] [Related]
11. The impact of genetic variation in IL28B, IFNL4 and HLA genes on treatment responses against chronic hepatitis C virus infection.
Sakhaee F; Ghazanfari M; Vaziri F; Jamnani FR; Davari M; Gharibzadeh S; Fateh R; Abdolrahimi F; Dizaji SP; Fateh A; Siadat SD
Infect Genet Evol; 2017 Oct; 54():330-337. PubMed ID: 28739427
[TBL] [Abstract][Full Text] [Related]
12. The interferon lambda 4 rs368234815 predicts treatment response to pegylated-interferon alpha and ribavirin in hemophilic patients with chronic hepatitis C.
Keshvari M; Alavian SM; Behnava B; Pouryasin A; Sharafi H
J Res Med Sci; 2016; 21():72. PubMed ID: 27904617
[TBL] [Abstract][Full Text] [Related]
13. IFNL4 ss469415590 Variant Is Associated with Treatment Response in Japanese HCV Genotype 1 Infected Individuals Treated with IFN-Including Regimens.
Miyamura T; Kanda T; Nakamoto S; Arai M; Nakamura M; Wu S; Jiang X; Sasaki R; Haga Y; Yasui S; Ooka Y; Chiba T; Imazeki F; Mikami S; Yokosuka O
Int J Hepatol; 2014; 2014():723868. PubMed ID: 25548683
[TBL] [Abstract][Full Text] [Related]
14. Telaprevir is effective given every 12 h at 750 mg with pegylated interferon-α2b and ribavirin to Japanese patients with HCV-1b IL28B rs8099917 TT.
Kawakami Y; Suzuki F; Karino Y; Toyota J; Kumada H; Chayama K
Antivir Ther; 2014; 19(3):277-85. PubMed ID: 24192751
[TBL] [Abstract][Full Text] [Related]
15. Association between IFNL4 rs368234815 polymorphism and sustained virological response in chronic hepatitis C patients undergoing PEGylated interferon/ribavirin therapy: A meta-analysis.
Xie X; Zhang L; Chen YZ
Hum Immunol; 2016 Jul; 77(7):609-15. PubMed ID: 27180197
[TBL] [Abstract][Full Text] [Related]
16. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin.
Yu JW; Wang GQ; Sun LJ; Li XG; Li SC
J Gastroenterol Hepatol; 2007 Jun; 22(6):832-6. PubMed ID: 17565637
[TBL] [Abstract][Full Text] [Related]
17. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.
Shepherd J; Brodin H; Cave C; Waugh N; Price A; Gabbay J
Health Technol Assess; 2004 Oct; 8(39):iii-iv, 1-125. PubMed ID: 15461877
[TBL] [Abstract][Full Text] [Related]
18. Confounding by Single Nucleotide Polymorphism rs117648444 (P70S) Affects the Association of Interferon Lambda Locus Variants with Response to Interferon-α-Ribavirin Therapy in Patients with Chronic Genotype 3 Hepatitis C Virus Infection.
Bhushan A; Ghosh S; Bhattacharjee S; Chinnaswamy S
J Interferon Cytokine Res; 2017 Aug; 37(8):369-382. PubMed ID: 28727946
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic drug monitoring of telaprevir in chronic hepatitis C patients receiving telaprevir-based triple therapy is useful for predicting virological response.
Furusyo N; Ogawa E; Murata M; Toyoda K; Ohnishi H; Eiraku K; Shimizu M; Harada Y; Mitsumoto F; Takayama K; Kainuma M; Okada K; Hayashi J
J Antimicrob Chemother; 2014 Feb; 69(2):483-90. PubMed ID: 24092661
[TBL] [Abstract][Full Text] [Related]
20. Clinical milestones for the prediction of severe anemia by chronic hepatitis C patients receiving telaprevir-based triple therapy.
Ogawa E; Furusyo N; Nakamuta M; Kajiwara E; Nomura H; Dohmen K; Takahashi K; Satoh T; Azuma K; Kawano A; Tanabe Y; Kotoh K; Shimoda S; Hayashi J;
J Hepatol; 2013 Oct; 59(4):667-74. PubMed ID: 23707372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
